Related references
Note: Only part of the references are listed.Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert D'Haens et al.
LANCET (2022)
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors
Alessandra Nerviani et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt
Renee H. Fiechter et al.
FRONTIERS IN IMMUNOLOGY (2021)
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
Stephen B. Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2020)
Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks
Thomas Chateau et al.
INFLAMMATORY BOWEL DISEASES (2020)
Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn's Disease: A Case Report and Review of the Literature
Satohiro Matsumoto et al.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS (2020)
Recurrent granulomatous cheilitis associated with Crohn's disease successfully treated with ustekinumab: case report and literature review
Carlos Taxonera et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Ustekinumab en un paciente con pioderma gangrenoso y enfermedad de Crohn refractaria
Paula García Cámara et al.
MEDICINA CLINICA (2019)
Ustekinumab Improves Paradoxical Enteropathy Associated With Psoriasis Arthritis
Jun Urushikubo et al.
INFLAMMATORY BOWEL DISEASES (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
IL-23 in inflammatory bowel diseases and colon cancer
Markus F. Neurath
CYTOKINE & GROWTH FACTOR REVIEWS (2019)
The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade
Anna Schurich et al.
RHEUMATOLOGY (2018)
Uveitis and Juvenile Psoriatic Arthritis or Psoriasis
Sherveen S. Salek et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
Pedro M. Machado et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics
Eric J. Mao et al.
BMJ OPEN GASTROENTEROLOGY (2018)
Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease
Kayci Huff-Hardy et al.
INFLAMMATORY BOWEL DISEASES (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
Eddie Y. Liu et al.
CASE REPORTS IN MEDICINE (2017)
Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis
Cristina Mugheddu et al.
DERMATOLOGIC THERAPY (2017)
Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases
Ripalta Colia et al.
ANNALS OF MEDICINE (2016)
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W. L. Teng et al.
NATURE MEDICINE (2015)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Denis Poddubnyy et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
In Situ Analysis of Interleukin-23-and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis
Heiner Appel et al.
ARTHRITIS AND RHEUMATISM (2013)
Enteropathic Spondyloarthritis: From Diagnosis to Treatment
Rosario Peluso et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
IL-23: One cytokine in control of autoimmunity
Andrew L. Croxford et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Measures of Symptoms and Disease Status in Ankylosing Spondylitis Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQOL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)
Jane Zochling
ARTHRITIS CARE & RESEARCH (2011)
Mucosal Inflammation in Spondylarthritides: Past, Present, and Future
Liesbet Van Praet et al.
CURRENT RHEUMATOLOGY REPORTS (2011)
Proinflammatory cytokines underlying the inflammation of Crohn's disease
Warren Strober et al.
CURRENT OPINION IN GASTROENTEROLOGY (2010)
Interactions between gut inflammation and arthritis/spondylitis
Peggy Jacques et al.
CURRENT OPINION IN RHEUMATOLOGY (2010)
Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease
Kai Wang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Selected Summary
Nadeem Z Jilani et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2009)
Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease
Carlo Salvarani et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
Jason R. Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Enteropathic arthritis
W Holden et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2003)
Review article: maintenance treatment of Crohn's disease
L Biancone et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
B Oppmann et al.
IMMUNITY (2000)
Share Paper
